Search Result
Results for "
blood lipids
" in MedChemExpress (MCE) Product Catalog:
6
Biochemical Assay Reagents
5
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-136346
-
|
Drug Metabolite
|
Cardiovascular Disease
|
2-Hydroxy atorvastatin lactone is a metabolite of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids .
|
-
-
- HY-135375
-
|
Drug Metabolite
|
Metabolic Disease
Inflammation/Immunology
|
O-Methyl Atorvastatin (hemicalcium) is an impurity of Atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids .
|
-
-
- HY-135151
-
Fluoroatorvastatin
|
Drug Metabolite
|
Cardiovascular Disease
|
Difluoro atorvastatin (Fluoroatorvastatin) is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively .
|
-
-
- HY-106818A
-
AJ-2615
|
Acyltransferase
Calcium Channel
|
Cardiovascular Disease
Metabolic Disease
|
Monatepil maleate (AJ-2615) is a potent and orally active Ca 2+-channel antagonist and a noncompetitive ACAT inhibitor. Monatepil maleate decreases blood pressure and improves plasma lipid metabolism. Monatepil maleate has the potential for the research of hyperlipidemia .
|
-
-
- HY-136185
-
|
Drug Metabolite
|
Others
|
Atorvastatin Epoxy Tetrahydrofuran Impurity is an impurity isolated oxidative degradation products of Atorvastatin (HY-B0589) . Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids.
|
-
-
- HY-130345
-
|
Platelet-activating Factor Receptor (PAFR)
|
Cardiovascular Disease
|
C18-PAF, octadecane PAF, is the ligand of platelet-activating factor and PAF G protein-coupled receptor (PAFR). C18-PAF has renovasodilator properties and antihypertensive lipid properties. C18-PAF increases renal blood flow and causes dose-dependent systemic hypotension .
|
-
-
- HY-101701
-
-
-
- HY-107863
-
Oligolevulose
|
Biochemical Assay Reagents
|
Metabolic Disease
|
Fructooligosaccharides (Oligolevulose) is a beneficial sugar which can be produced by the microbial flora. Fructooligosaccharides had no significant effect on blood glucose, blood lipid and serum acetate in diabetic model .
|
-
-
- HY-N0261
-
|
TNF Receptor
COX
|
Cardiovascular Disease
Inflammation/Immunology
|
Aurantio-obtusin is a anthraquinone compound that can be extracted from cassia seed. Aurantio-obtusin has the effects of decreasing blood pressure, decreasing blood lipids and anti-inflammatory.Aurantio-obtusin is an orally active vasodilator. Aurantio-obtusin ameliorates hepatic steatosis through AMPK/ autophagy- and AMPK/TFEB mediated inhibition of lipid accumulation .
|
-
-
- HY-123632
-
|
Cytochrome P450
|
Others
|
(3S,5S)-Atorvastatin sodium salt is a pregnane X receptor (PXR) activator and the inactive enantiomer of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor with lipid-lowering capabilities .
|
-
-
- HY-N0483
-
Phillygenol; Epipinoresinol methyl ether; (+)-Phillygenin
|
Reactive Oxygen Species
|
Others
|
Phillygenin (Phillygenol) is an active ingredient from Forsythia with many medicinal properties, such as antioxidant, reducing blood lipid, inhibition of low density lipoprotein oxidation.
|
-
-
- HY-U00340
-
|
PPAR
|
Metabolic Disease
|
PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.
|
-
-
- HY-136346S
-
|
Drug Metabolite
|
Cardiovascular Disease
|
Ortho-hydroxy atorvastatin lactone-d5 is deuterium labeled 2-Hydroxy atorvastatin lactone. 2-Hydroxy atorvastatin lactone is a metabolite of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids[1][2].
|
-
-
- HY-135381
-
|
Drug Metabolite
|
Cardiovascular Disease
|
3-Oxo Atorvastatin is an impurity of 3-Oxo Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids .
|
-
-
- HY-135380
-
|
Others
|
Cardiovascular Disease
|
Atorvastatin acetonide tert-butyl ester is a useful pharmaceutical intermediate in the preparation of Atorvastatin salts. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids .
|
-
-
- HY-124281
-
|
Others
|
Others
|
9(R)-PAHSA is a R-enantiomer of 9-PAHSA. 9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation .
|
-
-
- HY-124281A
-
|
Others
|
Others
|
9(S)-PAHSA is a S-enantiomer of 9-PAHSA. 9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation .
|
-
-
- HY-N2118
-
|
PPAR
PKA
Akt
p38 MAPK
ERK
|
Metabolic Disease
|
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .
|
-
-
- HY-144004
-
DSPE-PEG2000 Maleimide ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] ammonium
|
Liposome
|
Others
|
DSPE-PEG-Maleimide has DSPE phospholipid and maleimide to prepare nanostructured lipid carrier. DSPE-PEG-Maleimide extends blood circulation time and higher stability for encapsulated agents .
|
-
-
- HY-126852
-
P-Hydroxyatorvastatin lactone; 4-ATL
|
Drug Metabolite
|
Metabolic Disease
Inflammation/Immunology
|
4-Hydroxy Atorvastatin lactone is a metabolite of Atorvastatin (HY-B0589). Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids .
|
-
-
- HY-N7971
-
|
Endogenous Metabolite
|
Cardiovascular Disease
|
2-Hydroxy-1-Methoxyaporphine is an alkaloid that can be isolated from Nelumbo nucifera. 2-Hydroxy-1-Methoxyaporphine is the major active ingredient of the Chinese traditional medicine Jiang-Zhi-Ning .
|
-
-
- HY-135379
-
|
Drug Metabolite
|
Cardiovascular Disease
|
Atorvastatin acetonide is an impurity of Atorvastatin, and extracted from patent WO2011131605A1, Compound 4. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids .
|
-
-
- HY-141892A
-
|
Liposome
|
Others
|
DSPE-PEG Carboxylic acid (sodium), MW 2000 is a PEG-lipid that can be used to form micelles as nanoparticles for drug delivery. DSPE-PEG Carboxylic acid (sodium), MW 2000 increases the blood circulation time of liposomes .
|
-
-
- HY-135373
-
-
-
- HY-140740
-
|
Others
|
Cancer
|
DSPE-PEG-Maleimide, MW 5000 has DSPE phospholipid and maleimide to prepare nanostructured lipid carrier. DSPE-PEG-maleimide extends blood circulation time and higher stability for encapsulated agents .
|
-
-
- HY-120160
-
CP-86325
|
PPAR
|
Neurological Disease
Metabolic Disease
|
Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .
|
-
-
- HY-120980
-
TXB1
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Thromboxane B1 (TXB1) is one of thromboxane B (TXB) family members. Thromboxane is a member of the family of lipids known as eicosanoids. Thromboxane is named for its role in blood clot formation (thrombosis) .
|
-
-
- HY-N0640
-
Chrysontemin; Cyanidin 3-O-glucoside chloride
|
CD38
|
Neurological Disease
Metabolic Disease
|
Kuromanin chloride (Chrysontemin) is derived from mulberry leaves and has the effect of increasing blood sugar concentration and maintaining lipid metabolism balance to reduce obesity. Kuromanin chloride can inhibit CD38 enzymatic activities .
|
-
-
- HY-120160A
-
CP 86325 Sodium
|
PPAR
|
Neurological Disease
Metabolic Disease
|
Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective PPAR-γ (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .
|
-
-
- HY-160791
-
|
Others
|
Infection
Cancer
|
Claramine is a steroid polyamine with blood-brain barrier permeability. Claramine can regulate the properties of lipid membranes and protect cells from various biological toxins, including misfolded protein oligomers and biological protein-based toxins .
|
-
-
- HY-B2130
-
|
Reactive Oxygen Species
Endogenous Metabolite
|
Inflammation/Immunology
|
Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .
|
-
-
- HY-156276
-
|
PPAR
|
Metabolic Disease
|
SP4e is an activator of PPAR-γ, with the EC50 of 739 nM in HK-2 cells. SP4e reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .
|
-
-
- HY-156277
-
|
PPAR
|
Metabolic Disease
|
SP4f is an activator ofPPAR-γ, with the EC50 of 826 nM in HK-2 cells. SP4f reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .
|
-
-
- HY-161116
-
|
Others
|
Cancer
|
AD-5584 is an ACSS2 inhibitor with blood-brain permeability. AD-5584 can significantly reduce lipid storage, reduce colony formation, and increase cell death. AD-5584 has antitumor activity .
|
-
-
- HY-B2130A
-
Monosodium urate
|
Reactive Oxygen Species
Endogenous Metabolite
|
Metabolic Disease
|
Uric acid sodium (Monosodium urate), scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid sodium can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .
|
-
-
- HY-B0589
-
-
-
- HY-135377
-
(2E)-2,3-Dehydroxy Atorvastatin
|
Drug Metabolite
|
Metabolic Disease
Inflammation/Immunology
|
Atorvastatin 3-Deoxyhept-2E-Enoic Acid ((2E)-2,3-Dehydroxy Atorvastatin) is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids .
|
-
-
- HY-B0757A
-
Vitamin E Nicotinate
|
Reactive Oxygen Species
Endogenous Metabolite
|
Cardiovascular Disease
|
(±)-α-Tocopherol nicotinate, vitamin E - nicotinate, is an orally active fat-soluble antioxidant that prevents lipid peroxidation in cell membranes. (±)-α-Tocopherol nicotinate is hydrolysed in the blood to α -tocopherol and niacin and may be used in studies of related vascular diseases .
|
-
-
- HY-108257
-
-
-
- HY-144004A
-
DSPE-PEG5000 Maleimide ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-5000] ammonium
|
Liposome
|
Others
|
DSPE-PEG-Maleimide has DSPE phospholipid and maleimide to prepare nanostructured lipid carrier. DSPE-PEG-Maleimide extends blood circulation time and higher stability for encapsulated agents . DSPE-PEG5000-Mal ammonium contains PEG5000.
|
-
-
- HY-B0589E
-
-
-
- HY-N0712
-
|
Autophagy
|
Cardiovascular Disease
Inflammation/Immunology
|
Typhaneoside, extracted from Typha angustifolia L., Typhaneoside can inhibit the excessive autophagy of hypoxia/reoxygenation cells and increase the phosphorylation of Akt and mTOR. Typhaneoside has certain effects on the cardiovascular system, including lowering blood lipid levels, promoting antiatherosclerosis activities, as well as improving immune and coagulation function .
|
-
-
- HY-P2752
-
LPL
|
Endogenous Metabolite
|
Metabolic Disease
|
Lipoprotein lipase, Pseudomonas sp (LPL) is a multifunctional enzyme from adipose tissue, heart and skeletal muscle, islets and macrophages. Lipoprotein lipase promotes normal lipoprotein metabolism, delivery and utilization of tissue-specific substrates. Lipoprotein lipase catalyzes the rate-limiting step of lipids in blood circulation .
|
-
-
- HY-B0589C
-
|
Cytochrome P450
|
Metabolic Disease
|
(3S,5S)-Atorvastatin is a inactive enantiomer of Atorvastatin. (3S,5S)-Atorvastatin can activate pregnane X receptor (PXR). Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids .
|
-
-
- HY-B2130S1
-
|
Endogenous Metabolite
Reactive Oxygen Species
|
Inflammation/Immunology
|
Uric acid- 15N2 is the 15N labeled Uric acid . Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .
|
-
-
- HY-135380R
-
|
Others
|
Cardiovascular Disease
|
Atorvastatin acetonide tert-butyl ester (Standard) is the analytical standard of Atorvastatin acetonide tert-butyl ester. This product is intended for research and analytical applications. Atorvastatin acetonide tert-butyl ester is a useful pharmaceutical intermediate in the preparation of Atorvastatin salts. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids .
|
-
-
- HY-B0589S1
-
|
HMG-CoA Reductase (HMGCR)
Autophagy
|
Metabolic Disease
Inflammation/Immunology
|
Atorvastatin-d5 (sodium) is the deuterium labeled Atorvastatin sodium. Atorvastatin sodium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin sodium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3][4].
|
-
-
- HY-B0589S
-
|
HMG-CoA Reductase (HMGCR)
Autophagy
|
Metabolic Disease
Inflammation/Immunology
|
Atorvastatin-d5 (hemicalcium) is the deuterium labeled Atorvastatin. Atorvastatin hemicalcium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3].
|
-
-
- HY-135374
-
|
Drug Metabolite
|
Metabolic Disease
Inflammation/Immunology
|
(3R,5S)-Atorvastatin sodium is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively .
|
-
-
- HY-P99822
-
SHR-1209
|
Ser/Thr Protease
|
Metabolic Disease
|
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia .
|
-
- HY-129297
-
|
Endogenous Metabolite
|
Metabolic Disease
|
CMPF can be found in trace constituent of urine and blood. CMPF is a biomarker of type 2 diabetes. CMPF can act on the β cell and induces impaired mitochondrial function. CMPF decreases glucose-induced ATP accumulation, and induces oxidative stress. CMPF reverses hepatic lipid accumulation and improves insulin sensitivity in obese mice .
|
-
- HY-17379
-
CI-981; Atorvastatin hemicalcium
|
HMG-CoA Reductase (HMGCR)
Autophagy
Ferroptosis
|
Metabolic Disease
Inflammation/Immunology
|
Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively .
|
-
- HY-B2130S
-
|
Reactive Oxygen Species
Endogenous Metabolite
|
Inflammation/Immunology
|
Uric acid- 13C, 15N3 is the 13C-labeled and 15N-labeled Uric acid. Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation[1][2].
|
-
- HY-128144
-
|
Lipase
|
Metabolic Disease
|
Lalistat 2 is an inhibitor of many lipases especially Lysosomal acid lipase (LAL, IC50 = 152 nM), which is a key enzyme that degrades neutral lipids at an acidic pH in lysosomes. Lalistat 2 is commonly used to investigate the cell-specific functions of LAL and LAL deficiency in vitro, as well as specifically measure LAL activity in human blood samples or cells .
|
-
- HY-161117
-
|
Others
|
Cancer
|
AD-8007 is an acetyl CoA synthase 2 (ACSS2) inhibitor that can cross the blood-brain barrier. AD-8007 can significantly reduce lipid storage and cell colony formation in vitro models, and increase tumor cell death. AD-8007 has anti-cancer activity and can be used in the research of breast cancer .
|
-
- HY-148922
-
|
PPAR
|
Metabolic Disease
|
PPARα/γ agonist 2 is an orally active PPARα full agonist and PPARγ partial agonist. PPARα/γ agonist 2 activates PPARα and PPARγ with EC50 values of 0.95 μM and 0.91 μM respectively. PPARα/γ agonist 2 is also a PTP1B inhibitor. PPARα/γ agonist 2 is an anti-diabetic agent .
|
-
- HY-120657
-
|
Endogenous Metabolite
|
|
9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation. 9-PAHSA also improved carotid vascular calcification and attenuates cardiac hypertrophy and dysfunction in db/db mice. 9-PAHSA increases the viability of steatosis primary mouse hepatocytes (PMH). 9-PAHSA can be used in research on diabetes, inflammation, and cardiovascular disease .
|
-
- HY-134082A
-
|
Phospholipase
|
Inflammation/Immunology
|
(Z)-Oleyloxyethyl phosphorylcholine ((Z)-OPC) is an isomer of Oleyloxyethyl phosphorylcholine (OPC). Oleyloxyethyl phosphorylcholine is an inhibitor of secreted Phospholipase A2 (sPLA2), which is involved in the biosynthesis of proinflammatory lipid media. Oleyloxyethyl phosphorylcholine can be used to study inflammatory diseases. Oleyloxyethyl phosphorylcholine also modified the red blood membrane and was used to bind the oxygen-carrying liquid perfluorocarbons as an antivenom agent to reduce toxin-induced hemolysis .
|
-
- HY-146398
-
|
AMPK
|
Metabolic Disease
|
AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .
|
-
- HY-17379R
-
CI-981 (Standard); Atorvastatin hemicalcium (Standard)
|
HMG-CoA Reductase (HMGCR)
Autophagy
Ferroptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Atorvastatin (hemicalcium salt) (Standard) is the analytical standard of Atorvastatin (hemicalcium salt). This product is intended for research and analytical applications. Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively .
|
-
- HY-106784A
-
|
Others
|
Neurological Disease
|
(E)-Ajoene is a oxygenated ajoene and organosulfur compound, which can be acquired via allicin decomposing. The polysulfides from garlic can be converted by human red blood cells into hydrogen sulfide (H2S) and allyl glutathione. (E)-Ajoene has been proved to show neuroprotective effects against ischemic damage. (E)-Ajoene is orally active to inhibit lipid peroxidation. (E)-Ajoene increases the number of cresyl violet-positive neurons and decreases the number of reactive gliosis in the CA1 region .
|
-
- HY-137499
-
|
Liposome
Endogenous Metabolite
|
Neurological Disease
|
NT1-O12B, an endogenous chemical and a neurotransmitter-derived lipidoid (NT-lipidoid), is an effective carrier for enhanced brain delivery of several blood-brain barrier (BBB)-impermeable cargos. Doping NT1-O12B into BBB-impermeable lipid nanoparticles (LNPs) gives the LNPs the ability to cross the BBB. NT-lipidoids formulation not only facilitate cargo crossing of the BBB, but also delivery of the cargo into neuronal cells for functional gene silencing or gene recombination .
|
-
- HY-131688
-
|
Others
|
Inflammation/Immunology
|
2-Chlorohexadecanoic acid, an inflammatory lipid mediator, interferes with protein palmitoylation,induces ER-stress markers, reduced the ER ATP content, and activates transcription and secretion of IL-6 as well as IL-8.2-Chlorohexadecanoic acid disrupts the mitochondrial membrane potential and induces procaspase-3 and PARP cleavage.2-Chlorohexadecanoic acid can across blood-brain barrier (BBB) and compromises ER- and mitochondrial functions in the human brain endothelial cell line hCMEC/D3 .
|
-
- HY-B1028
-
-
Cat. No. |
Product Name |
Type |
-
- HY-144004
-
DSPE-PEG2000 Maleimide ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] ammonium
|
Drug Delivery
|
DSPE-PEG-Maleimide has DSPE phospholipid and maleimide to prepare nanostructured lipid carrier. DSPE-PEG-Maleimide extends blood circulation time and higher stability for encapsulated agents .
|
-
- HY-141892A
-
|
Drug Delivery
|
DSPE-PEG Carboxylic acid (sodium), MW 2000 is a PEG-lipid that can be used to form micelles as nanoparticles for drug delivery. DSPE-PEG Carboxylic acid (sodium), MW 2000 increases the blood circulation time of liposomes .
|
-
- HY-B0757A
-
Vitamin E Nicotinate
|
Biochemical Assay Reagents
|
(±)-α-Tocopherol nicotinate, vitamin E - nicotinate, is an orally active fat-soluble antioxidant that prevents lipid peroxidation in cell membranes. (±)-α-Tocopherol nicotinate is hydrolysed in the blood to α -tocopherol and niacin and may be used in studies of related vascular diseases .
|
-
- HY-144004A
-
DSPE-PEG5000 Maleimide ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-5000] ammonium
|
Drug Delivery
|
DSPE-PEG-Maleimide has DSPE phospholipid and maleimide to prepare nanostructured lipid carrier. DSPE-PEG-Maleimide extends blood circulation time and higher stability for encapsulated agents . DSPE-PEG5000-Mal ammonium contains PEG5000.
|
-
- HY-107863
-
Oligolevulose
|
Biochemical Assay Reagents
|
Fructooligosaccharides (Oligolevulose) is a beneficial sugar which can be produced by the microbial flora. Fructooligosaccharides had no significant effect on blood glucose, blood lipid and serum acetate in diabetic model .
|
-
- HY-137499
-
|
Drug Delivery
|
NT1-O12B, an endogenous chemical and a neurotransmitter-derived lipidoid (NT-lipidoid), is an effective carrier for enhanced brain delivery of several blood-brain barrier (BBB)-impermeable cargos. Doping NT1-O12B into BBB-impermeable lipid nanoparticles (LNPs) gives the LNPs the ability to cross the BBB. NT-lipidoids formulation not only facilitate cargo crossing of the BBB, but also delivery of the cargo into neuronal cells for functional gene silencing or gene recombination .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99822
-
SHR-1209
|
Ser/Thr Protease
|
Metabolic Disease
|
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B2130S1
-
|
Uric acid- 15N2 is the 15N labeled Uric acid . Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .
|
-
-
- HY-B0589S
-
|
Atorvastatin-d5 (hemicalcium) is the deuterium labeled Atorvastatin. Atorvastatin hemicalcium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3].
|
-
-
- HY-B2130S
-
|
Uric acid- 13C, 15N3 is the 13C-labeled and 15N-labeled Uric acid. Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation[1][2].
|
-
-
- HY-136346S
-
|
Ortho-hydroxy atorvastatin lactone-d5 is deuterium labeled 2-Hydroxy atorvastatin lactone. 2-Hydroxy atorvastatin lactone is a metabolite of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids[1][2].
|
-
-
- HY-B0589S1
-
|
Atorvastatin-d5 (sodium) is the deuterium labeled Atorvastatin sodium. Atorvastatin sodium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin sodium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3][4].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: